$MTP News
Last published 3y ago
- 3y agoMTPMidatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal DiseaseACCESS NewswireABINGDON, OXFORDSHIRE / ACCESSWIRE / March 27, 2023 / Midatech Pharma PLC , a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, is pleased
- 3y agoMTPMidatech Pharma PLC Announces Further re: Notice of General MeetingACCESS NewswireMidatech Pharma PLC Further re: Notice of General Meeting - Correction of Typographical ErrorsABINGDON, OXFORDSHIRE / ACCESSWIRE / March 10, 2023 / Further to the
- 3y agoMTPMidatech Pharma PLC Announces Posting of Circular and Notice of General MeetingACCESS NewswireProposed Share Consolidation, Authority to Allot Shares, Disapplication of Pre-Emption Rights, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIMABINGDON, OXFORDSHIRE / ACCESSWIRE /
- 3y agoMTPMidatech Pharma PLC Announces Closing of $6.0m Private Placement & Broker ChangeACCESS NewswireABINGDON, UK / ACCESSWIRE / February 15, 2023 / Midatech Pharma PLC , a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces the
- 3y agoMTPMidatech Pharma PLC Announces Private Placement Raising US $6.0 millionACCESS NewswireTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA,
- 3y agoBIOAFMTPBioasis Technologies Inc. Mails Management Information Circular for Annual and Special Meeting of SecurityholdersGlobeNewswireNEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF, TSX.V:BTI)) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
- 3y agoBIOAFMTPBioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plcGlobeNewswireNEW HAVEN, Conn., Dec. 19, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF, TSX.V:BTI)) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
- 3y agoBIOAFMTPBioasis Technologies Inc. Announces Merger with Midatech Pharma plcGlobeNewswireNEW HAVEN, Conn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF, TSX.V:BTI)) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
- 4y agoMTPMidatech Pharma PLC Announces ADR Ratio ChangeACCESS NewswireABINGDON, OXFORDSHIRE / ACCESSWIRE / September 14, 2022 / Midatech Pharma (AIM:MTPH)(NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces a ratio change on its American Depositary Rec
- 4y agoMTPMidatech Pharma PLC Announces Interim Results for the Six Months to 30 June 2022ACCESS NewswireABINGDON, OXFORDSHIRE / ACCESSWIRE / September 14, 2022 / Midatech Pharma Plc ((AIM:MTPH, NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its unaudited interim results for
- 4y agoMTPMidatech Pharma PLC Announces Fast Track Designation for MTX110 DevelopmentACCESS NewswireFast Track Designation Granted to MTX110 Development for the Treatment of Recurrent Glioblastoma ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 1, 2022 / Midatech Pharma PLC (AIM:MTPH.L); (NASDAQ:MTP), an R&D biotechnology company focused on improving the bi
- 4y agoMTPMidatech Pharma PLC Announces Posting of Annual Report & Notice of AGMACCESS NewswireABINGDON, OXFORDSHIRE / ACCESSWIRE / May 24, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces that its Notice of Annual General Meetin
- 4y agoMTPMidatech Pharma PLC Announces Results for the Year Ended 31 December 2021ACCESS NewswireABINGDON, OXFORDSHIRE / ACCESSWIRE / April 26, 2022 / Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its audited preliminary results for the year e
- 4y agoMTPMidatech Pharma PLC Announces Receipt of NASDAQ NoticeACCESS NewswireABINGDON, OXFORDSHIRE / ACCESSWIRE / April 14, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written notification (
- 4y agoMTPMidatech Pharma PLC Announces R&D Collaboration with Janssen on Second MoleculeACCESS NewswireABINGDON, UK / ACCESSWIRE / March 9, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce an extension of its existing R&D col
- 4y agoMTPMidatech Pharma PLC Announces Appointment of Nominated and Financial AdviserACCESS NewswireABINGDON, UK / ACCESSWIRE / March 8, 2022 / Midatech Pharma PLC ((AIM:MTPH, NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicine, is pleased to announce the appointment of Strand Hanson Lim
- 4y agoMTPMidatech Pharma PLC Announces Extension of Janssen collaboration re Q-SpheraACCESS NewswireMidatech announces extension of R&D collaboration with Janssen focused on Q-Sphera technology ABINGDON, UK / ACCESSWIRE / January 17, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-deli
- 4y agoMTPMidatech Pharma PLC Announces IND Application for MTX110 Study in GBM EffectiveACCESS NewswireInvestigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective ABINGDON, OXFORDSHIRE / ACCESSWIRE / December 13, 2021 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on
- 5y agoMTPMidatech Pharma PLC Announces Notice of Interim ResultsACCESS NewswireABINGDON, OXFORDSHIRE / ACCESSWIRE / September 6, 2021 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it will release its interim res
- 5y agoGSKMTPTYO:4528TYO:4568Midatech Pharma PLC Announces Appointment of Chief Scientific OfficerACCESS NewswireMidatech Pharma PLC ('Midatech' or the 'Company') Midatech Strengthens Management Team with Appointment of Dr. Dmitry Zamoryakhin as Chief Scientific Officer ABINGDON, OXFORDSHIRE / ACCESSWIRE / July 12, 2021 / Midatech Pharma PLC ((AIM:MTPH, NASDAQ:MTP
- 5y agoGOLDMTPPIRSRIDE+1Thinking about buying stock in Pieris Pharmaceuticals, Midatech Pharma, ContextLogic, Barrick Gold, or Lordstown Motors?PR NewswireNEW YORK, June 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PIRS, MTP, WISH, GOLD, and RIDE. T
- 5y agoMTPMidatech Pharma PLC Announces Breakthrough Data Using Q-Sphera TechnologyACCESS NewswireBreakthrough data on the successful encapsulation of a biologic using Q-Sphera technology Significant progress across multiple other R&D programmes ABINGDON, OXFORDSHIRE/ ACCESSWIRE / June 17, 2021 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), an R&D
- 5y agoMTPMidatech Pharma PLC Announces Investor Webinar Scheduled for 17 June 2021ACCESS NewswireABINGDON, UK / ACCESSWIRE / June 9, 2021 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, will be hosting an investor webinar focused on the Company
- 5y agoMTPMidatech Pharma PLC Announces Posting of Annual Report & Notice of AGMACCESS NewswireABINGDON, OXFORDSHIRE / ACCESSWIRE / May 21, 2021 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines announces that its Notice of Annual General Meeti
- 5y agoMTPMidatech Pharma PLC Announces Results for the Year Ended 31 December 2020ACCESS NewswirePreliminary Results for the Year Ended 31 December 2020 ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 30, 2021 / Midatech Pharma PLC (AIM:MTPH.L); (NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of
- 5y agoMTPMidatech Pharma PLC Announces MTX110 Update & Headline Results for 2020ACCESS NewswireNon-binding Heads of Terms for Co-development of MTX110; Unaudited Headline Results for the Year Ended 31 December 2020
- 5y agoMTPMidatech Pharma PLC Announces Exercise of Warrants and Issue of EquityACCESS NewswireABINGDON, OXFORDSHIRE / ACCESSWIRE / February 17, 2021 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has issued to certain US investors 61,363 American Depositary Shares ("ADSs"), representing 306,815 ordinary shares of 0.1p each in the Company ("New Ordinary Shares"), in ...
- 5y agoMTPMidatech Pharma PLC Announces Business UpdateACCESS NewswireMidatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces a number of updates:
- 5y agoMTPMidatech Pharma PLC Announces MTX110 Programmes to be presented at ISPNO 2020ACCESS NewswireMTX110 Programmes to be Presented at The International Symposium on Pediatric Neuro-Oncology, Karuizawa, Japan (ISPNO 2020)
- 5y agoMTPMidatech Pharma PLC Announces Launch of new websiteACCESS NewswireMidatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that the Company has launched a new corporate website. The website address is unchanged at .
- 5y agoMTPMidatech Pharma PLC Announces MTX110 presented at 2020 Annual SNO ConferenceACCESS NewswireABINGDON, OXFORDSHIRE / ACCESSWIRE / November 24, 2020 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to note that the latest research on MTX110 was presented by its collaborators at the recent annual meeting of the Society of Neuro-Oncology (SNO2020 Virtual Conference). Links to the Ab ...
- 6y agoMTPMidatech Pharma PLC Announces Headline Results of MTX110 Phase I DIPG StudyACCESS NewswireHeadline Results of MTX110 Phase I DIPG Study
- 6y agoMTPMidatech Pharma plc (MTP) CEO Stephen Stamp on Q2 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
- 6y agoMTPMidatech Pharma PLC Announces Interim results - 6 months ended 30 June 2020ACCESS NewswireR&D Collaboration Strategy Gaining Traction
- 6y agoMTPMidatech Pharma PLC Announces Investor WebinarACCESS NewswireMidatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, will be hosting an investor webinar at 2.00pm London time on 10 September 2020, the day of the release of the Company's interim results for the six months ended 30 June 2020.
- 6y agoMTPMidatech Pharma PLC Announces Exercise of Warrants and Issue of EquityACCESS NewswireMidatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has issued to certain US investors 500,000 American Depositary Shares ("ADSs"), representing 2,500,000 ordinary shares of 0.1p each in the Company ("New Ordinary Shares"), in connection with the exercise of pre-existing warrants ...
- 6y agoMTPMidatech Pharma PLC Announces Registration Statement Declared EffectiveACCESS NewswireMidatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that the U.S. Securities and Exchange Commission ("SEC") has declared effective the Company's registration statement on Form F-1 (the "Registration Statement") relating to the permitted resale of up to 12,695,445 ordinary shares, nominal ...
- 6y agoMTPMidatech Pharma PLC Announces Corporate Update & Formal Sale Process TerminationACCESS NewswireMidatech (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces it has terminated the formal sale process initiated by the Company on 20 April 2020. The formal sale process, as referred to in the City Code on Takeovers and Mergers (the "Code"), granted dispensations from Rule 2 of the Code such that any intere ...
- 6y agoOPKMTPGNPXONTXOrphan Drug Development to Target Increasing Incidence of Liver CancerPR NewswireThe rising incidence of liver cancer and growing research activities for developing novel treatments plus the availability of newer drugs and...
- 6y agoMTPMidatech Pharma PLC announces Collaboration for the Q-Sphera platformACCESS NewswireMidatech Pharma's next generation drug delivery technologies to be applied to new modalities in collaboration with a European pharmaceutical company.
- 6y agoMTPMidatech Pharma PLC announces Publication of Annual ReportACCESS NewswireMidatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines announces that electronic copies of its Annual Report and Accounts for the year ended 31 December 2019 are now available from the Company's investor relations website at . Hard copies of the 2019 Annual Report and Accounts are expected to be poste ...
- 6y agoMTPMidatech Pharma PLC Announces Grant of OptionsACCESS NewswireABINGDON, OXFORDSHIRE ACCESSWIRE / June, 17, 2020 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines announces that options over a total of 1,401,000 ordinary shares of 0.1 pence each in the capital Company have been granted to employees under the 2014 Midatech Pharma plc Enterprise Management I ...
- 6y agoMTPMidatech Pharma PLC Announces Results for the year ended 31 December 2019ACCESS NewswirePreliminary results for the year ended 31 December 2019
- 6y agoMTPMidatech Pharma PLC Announces Purported Termination of MTX110 Licence AgreementACCESS NewswireThis Announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Upon the publication of this Announcement, this inside information is now considered to be in the public domain.
- 6y agoMTPRDYMidatech Pharma PLC Announces Research collaboration with Dr Reddy’sACCESS NewswireMidatech Pharma's next generation drug delivery technologies for comprehensively improving bio-delivery and bio-distribution to be applied to existing medicines in collaboration with Dr Reddy's Laboratories.
- 6y agoMTPMidatech Pharma PLC Announces Closing of US$3.0m Registered Direct OfferingACCESS NewswireMidatech Pharma PLC (LSE:MTPH)(NASDAQ:MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, today announced the closing of its previously announced registered direct offering (the "Offering") of 1,818,182 of its American Depositary Shares ("ADSs") (each ADS representing five of the Company's ordinary shares (the "New Ordinary Shares")) ...
- 6y agoMTPMidatech Pharma PLC - Correction: UK Placing to Raise £1.8 millionACCESS NewswireCorrection: The following amendment has been made to the 'UK Placing to Raise £1.8 million' announcement released on 18 May 2020.
- 6y agoMTPMidatech Pharma PLC Announces UK Placing to Raise £1.8 millionACCESS NewswireNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CA ...
- 6y agoMTPMidatech Pharma PLC Announces US$3.0 Million Registered Direct OfferingACCESS NewswireMidatech Pharma PLC ("Midatech" or the "Company") (AIM:MTPH.L; NASDAQ:MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that it has entered into definitive binding agreements with institutional investors (the "Investors") for the purchase in a registered direct offering (the "Offering") of 1,818,182 of its Ame ...
- 6y agoMTPMidatech Pharma PLC Announces Headline Results for the Year Ended 31 Dec 2019ACCESS NewswireThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.